logo

This site is intended for X healthcare Professionals - LTS

Neuron forest. A middle-aged menopausal woman surrounded by fiery neuron trees is sweating and tugging at her neckline.

A closer look at menopause and VMSmenopause

The menopausal transition can bring a constellation of unfamiliar and unsettling symptoms1

Image: Not an actual patient.

SubgroupPADCEV +
pembrolizumab
mOS, Months (Events/N)		Chemotherapy
mOS, Months (Events/N)		Hazard Ratio (95% CI)
Overall31.5 (133/442)16.1 (226/444) 0.47 (0.38, 0.58)
Age
<65 yearsNR (39/144)19.7 (58/135) 0.46 (0.30, 0.71)
≥65 years31.5 (94/298)14.6 (168/309) 0.48 (0.38, 0.63)
Region
North America25.6 (40/103)21.2 (42/85) 0.71 (0.44, 1.12)
EuropeNE (56/172)13.9 (110/197) 0.40 (0.28, 0.56)
Rest of worldNE (37/167)16.4 (74/162) 0.41 (0.27, 0.61)
     

Secondary Jump Link Section 1 - Above this heading.

During the menopausal transition, many women experience sleep disturbances, changes in mood and cognitive performance, migraine, and Vasomotor Symptoms (VMS), also known as hot flushes and night sweats. They also undergo physical changes, which can continue long into postmenopause, including changes in body shape, osteoporosis, increased risk of cardiovascular events, ageing of hair and skin, and vulvovaginal atrophy.1

Vasomotor Symptoms are the most commonly reported symptoms of the menopausal transition. Up to 80% of women are affected by VMS during the menopausal transition.2

VMS arise from heightened neuronal activity in the hypothalamus VMS & Menopause. This leads to hypertrophy of KNDy neurons and altered activity in the temperature control centre. The resulting VMS include the uncomfortable feeling of heat and sweating, which can disrupt women’s daily lives.1-5

Secondary Jump Link Section 2 - Top of the Card

Burden of VMS First Nav Title

The Hypothalamus & VMS

Xospata Support Solution SM

Secondary Jump Link Section 3 - Here

Link Style :-

Font size of Text as 'Step 0' and Icon with Size as 'S'

Font size of Text as 'Step-1' and  Icon with Size as 'XS'

Font size of Text as 'Step-2' and  Icon with Size as '2XS'

Secondary Jump Link Section 4 - Here

Icon Style :-

Icon with Size as 'S'

Icon with Size as 'M'

Icon with Size as 'L'

Secondary Icon

As an anti-counterfeit measure, Astellas commissioned a formal Committee comprised of leaders from multiple stakeholder functions (quality assurance, supply chain, etc.), and has also established a product security function to oversee daily activities relevant to product-related security risks. These entities monitor the global market for suspicious activities affecting Astellas products, and implement countermeasures targeting not only counterfeit/falsified medicines, but also diversion, theft and other illicit activities that potentially affect our products and/or present a potential risk to patients. Astellas systematically introduces anti-counterfeit measures, including, but not limited to, product serialization as stipulated by current regulations and pharmaceutical laws.

 

In addition, Astellas regularly engages in various collaborative activities with other members of the pharmaceutical industry to help prevent the spread of counterfeit/falsified medicines. We also proactively support and cooperate with national regulatory and judicial authorities in the prevention of counterfeit/falsified medicines.

What really gets me about menopause is the hot flushes. Suddenly I'm turning red, and there's nothing I can do about it.

This is a Test. 

On-market portfolio includes transformative therapies in oncology, ophthalmology, urology, immunology, and women's healthophthalmology. 

Patient PT@001 Age= 45 years old with a BMI of 35.0, classified as obese, and has a ^50% probability of health risk. ⚠️ High cholesterol – recheck in 3 months.

 

Patient PT#002, aged = 30, has a BMI of ~ 22.4, falls within the normal range, and carries only a 10% health risk. ✔️ Healthy; active lifestyle.

 

Patient PT#003 is age= 60 years old with a BMI of ~31.5, categorized as obese, and faces a 65% risk of developing related health issues. #Diabetic & ↑BP – monitor closely.

 

Patient PT*004, = 38, has a BMI of 29.8, considered overweight, with a 35% probability of risk. Mild sleep apnea – test @ next visit.

 

Patient PT!005 is = 52 years old with a BMI of ~ 27.2, & also overweight, and shows a 40% risk level. Smoker – risk ↑ by 10%.

 

Patient PT$006, at = 70 years old, has a BMI of 33.1, marked as obese, with a 75% risk for health complications. ⚠️ History of heart disease.

 

Patient PT&007 is = 25 years old and has a BMI of 19.5, categorized as underweight, with a 15% risk. “Low BMI” – monitor nutrition.

 

Patient PT(008), aged = 49, presents a BMI of 28.0, which is overweight, and has a 45% chance of health-related risk. Stress reported – 🧠 mental health.

#Patients are dummy, ^data are for QA purpose